RZG Fact Sheet: Invesco S&P SmallCap 600 Pure Growth ETF
Share
$60.33
close, Nov 18, 2026
Over the year to Nov 18, 2026, RZG returned +17.2% in total and charged 0.35% a year.
- 1-year total return
- +17.2%
- to Nov 18, 2026
- Expense ratio
- 0.35%
- a year
- Net assets
- $113m
- on Nov 17, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
RZG $11,724 +17.2% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month−2.2%
3 months−12.6%
Year to date+11.5%
1 year+17.2%
3 years+49.6%
5 years+10.6%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Progyny Inc1.99%
Acadian Asset Management Inc1.97%
Protagonist Therapeutics Inc1.89%
Arcutis Biotherapeutics Inc1.87%
Clear Secure Inc1.77%
Chefs' Warehouse Inc1.73%
TG Therapeutics Inc1.62%
ACM Research Inc1.54%
Dave Inc1.53%
Sezzle Inc1.49%
RZG top ten by weight, 17.4% of the fund, of its 128 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the S&P SmallCap 600 Pure Growth Index · First traded Mar 7, 2006 · Benchmark Its own holdings, as of Nov 17, 2026